Compare Merck & Co., Inc. (MRK) vs Invesco NASDAQ 100 ETF (QQQM) Price & Performance

Merck & Co., Inc.Trade

Invesco NASDAQ 100 ETFTrade

Price performance (Past 24H)

Key statistics

Merck & Co., Inc. vs Invesco NASDAQ 100 ETF — how do they compare? Merck & Co., Inc. trades at $126.19 (market cap $307.25B), while Invesco NASDAQ 100 ETF trades at $291.91. The key difference: Merck & Co., Inc. pays a 2.73% dividend while Invesco NASDAQ 100 ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, Invesco NASDAQ 100 ETF nearer its low. Which is the better fit depends on your goals.

	MRK	QQQM
Market Cap	$307.25B	—
Sector	Health	Broad Market / Factor
52-Week High	$129.52	$307.23
52-Week Low	$77.60	$228.02
Enterprise Value	$350.66B	—
Dividend Yield	2.73%	—

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Merck & Co., Inc.

Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamentals including a net income margin of 13.59% and ROE of 18.97%. Recent earnings beats and the acquisition of Terns Pharmaceuticals for approximately $6.7 billion highlight strategic growth initiatives. The stock is supported by a consensus analyst price target of $137.30, indicating potential upside from current levels.

The outlook for Merck is positive, driven by robust profitability, strategic acquisitions, and analyst confidence. Key risks include rising debt levels, with debt-to-asset ratio increasing to 36.06% in 2025, and competitive pressures in the oncology space. Investors should weigh strong cash flow generation against execution risks in integrating recent acquisitions.

Invesco NASDAQ 100 ETF

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

MRK

Over 180 companies develop 200+ PD-1/PD-L1 inhibitors, reshaping cancer treatment landscape.Delveinsight · 4 hours agoBullish Schwab U.S. Dividend Equity ETF (SCHD) remains a Buy for strong dividends and growth potential.Seeking Alpha · 1 day agoBullish Merck rated Strong Buy on oncology growth and new LIPFENDRA launch for cholesterol controlSeeking Alpha · 4 days agoBullish View details →

QQQM

Investors poured billions into South Korea ETFs and semiconductors amid market shifts last week.ETF Trends · 1 day agoBullish Invesco Nasdaq 100 ETF (QQQM) hits $100B AUM, remains top growth index fund despite new cheaper rivals.ETF Trends · 1 day agoBullish Four ETFs near $100B milestone, highlighting investor demand for growth, dividends, safety, and diversification.ETF Trends · 1 day agoBullish View details →

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

About Invesco NASDAQ 100 ETF

QQQM is an ETF designed to track the performance of the NASDAQ-100 Index. It provides exposure to the 100 largest non-financial companies listed on the NASDAQ. Positioned as a lower-cost and more long-term-investor-friendly alternative to its peer QQQ, QQQM offers the same fundamental market exposure but typically has a lower share price and is structured to appeal to investors focused on accumulation rather than active trading.